153 related articles for article (PubMed ID: 30527105)
1. Maternal and perinatal outcomes associated with the use of renin-angiotensin system (RAS) blockers for chronic hypertension in early pregnancy.
Ahmed B; Tran DT; Zoega H; Kennedy SE; Jorm LR; Havard A
Pregnancy Hypertens; 2018 Oct; 14():156-161. PubMed ID: 30527105
[TBL] [Abstract][Full Text] [Related]
2. Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence.
Polifka JE
Birth Defects Res A Clin Mol Teratol; 2012 Aug; 94(8):576-98. PubMed ID: 22807387
[TBL] [Abstract][Full Text] [Related]
3. Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: A systematic review and meta-analysis.
Buawangpong N; Teekachunhatean S; Koonrungsesomboon N
Pharmacol Res Perspect; 2020 Oct; 8(5):e00644. PubMed ID: 32815286
[TBL] [Abstract][Full Text] [Related]
4. Increased rate of birth defects after first trimester use of angiotensin converting enzyme inhibitors - Treatment or hypertension related? An observational cohort study.
Hoeltzenbein M; Tissen-Diabaté T; Fietz AK; Zinke S; Kayser A; Meister R; Weber-Schoendorfer C; Schaefer C
Pregnancy Hypertens; 2018 Jul; 13():65-71. PubMed ID: 30177074
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits.
Pucci M; Sarween N; Knox E; Lipkin G; Martin U
Expert Rev Clin Pharmacol; 2015 Mar; 8(2):221-31. PubMed ID: 25612630
[TBL] [Abstract][Full Text] [Related]
6. Pregnancy Outcome After First Trimester Use of Methyldopa: A Prospective Cohort Study.
Hoeltzenbein M; Beck E; Fietz AK; Wernicke J; Zinke S; Kayser A; Padberg S; Weber-Schoendorfer C; Meister R; Schaefer C
Hypertension; 2017 Jul; 70(1):201-208. PubMed ID: 28533329
[TBL] [Abstract][Full Text] [Related]
7. Maternal and perinatal outcomes of extreme obesity in pregnancy.
Crane JM; Murphy P; Burrage L; Hutchens D
J Obstet Gynaecol Can; 2013 Jul; 35(7):606-611. PubMed ID: 23876637
[TBL] [Abstract][Full Text] [Related]
8. Pregnancy outcome after first trimester use of angiotensin AT1 receptor blockers: an observational cohort study.
Hoeltzenbein M; Tissen-Diabaté T; Fietz AK; Zinke S; Kayser A; Meister R; Weber-Schoendorfer C; Schaefer C
Clin Res Cardiol; 2018 Aug; 107(8):679-687. PubMed ID: 29574489
[TBL] [Abstract][Full Text] [Related]
9. Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies.
Kunutsor SK; Blom AW; Whitehouse MR; Kehoe PG; Laukkanen JA
Eur J Epidemiol; 2017 Nov; 32(11):947-959. PubMed ID: 28752198
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Pregnancies for Women Undergoing Endoscopy While They Were Pregnant: A Nationwide Cohort Study.
Ludvigsson JF; Lebwohl B; Ekbom A; Kiran RP; Green PH; Höijer J; Stephansson O
Gastroenterology; 2017 Feb; 152(3):554-563.e9. PubMed ID: 27773807
[TBL] [Abstract][Full Text] [Related]
11. Beta-blockers increase the risk of being born small for gestational age or of being institutionalised during infancy.
Xie RH; Guo Y; Krewski D; Mattison D; Walker MC; Nerenberg K; Wen SW
BJOG; 2014 Aug; 121(9):1090-6. PubMed ID: 24628701
[TBL] [Abstract][Full Text] [Related]
12. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
Diav-Citrin O; Shechtman S; Halberstadt Y; Finkel-Pekarsky V; Wajnberg R; Arnon J; Di Gianantonio E; Clementi M; Ornoy A
Reprod Toxicol; 2011 May; 31(4):540-5. PubMed ID: 21338666
[TBL] [Abstract][Full Text] [Related]
13. Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa.
Molvi SN; Mir S; Rana VS; Jabeen F; Malik AR
Arch Gynecol Obstet; 2012 Jun; 285(6):1553-62. PubMed ID: 22249781
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.
Bangalore S; Kumar S; Kjeldsen SE; Makani H; Grossman E; Wetterslev J; Gupta AK; Sever PS; Gluud C; Messerli FH
Lancet Oncol; 2011 Jan; 12(1):65-82. PubMed ID: 21123111
[TBL] [Abstract][Full Text] [Related]
15. Melanoma and Non-Melanoma Skin Cancer Associated with Angiotensin-Converting-Enzyme Inhibitors, Angiotensin-Receptor Blockers and Thiazides: A Matched Cohort Study.
Nardone B; Majewski S; Kim AS; Kiguradze T; Martinez-Escala EM; Friedland R; Amin A; Laumann AE; Edwards BJ; Rademaker AW; Martini MC; West DP
Drug Saf; 2017 Mar; 40(3):249-255. PubMed ID: 27943160
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis.
Bellos I; Pergialiotis V; Papapanagiotou A; Loutradis D; Daskalakis G
Am J Obstet Gynecol; 2020 Oct; 223(4):525-537. PubMed ID: 32199925
[TBL] [Abstract][Full Text] [Related]
17. In Utero Antihypertensive Medication Exposure and Neonatal Outcomes: A Data Linkage Cohort Study.
Fitton CA; Fleming M; Steiner MFC; Aucott L; Pell JP; Mackay DF; Mclay JS
Hypertension; 2020 Mar; 75(3):628-633. PubMed ID: 31884860
[TBL] [Abstract][Full Text] [Related]
18. Association between gestational weight gain and perinatal outcomes in women with chronic hypertension.
Yee LM; Caughey AB; Cheng YW
Am J Obstet Gynecol; 2017 Sep; 217(3):348.e1-348.e9. PubMed ID: 28522319
[TBL] [Abstract][Full Text] [Related]
19. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.
Toh S; Reichman ME; Houstoun M; Ross Southworth M; Ding X; Hernandez AF; Levenson M; Li L; McCloskey C; Shoaibi A; Wu E; Zornberg G; Hennessy S
Arch Intern Med; 2012 Nov; 172(20):1582-9. PubMed ID: 23147456
[TBL] [Abstract][Full Text] [Related]
20. Treatment with Optimal Dose Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Has a Positive Effect on Long-Term Survival in Older Individuals (Aged >70 Years) and Octogenarians with Systolic Heart Failure.
Sargento L; Simões AV; Longo S; Lousada N; Dos Reis RP
Drugs Aging; 2016 Sep; 33(9):675-83. PubMed ID: 27568454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
